Table 3.

Common solid tumour chemotherapy toxicities19

Class of drugDrug nameCancer sitesCommon toxicity
Alkylating agentsCarboplatinOvarian and small cell lung cancers, germ cell tumoursOtotoxicity, myelosuppression
CisplatinTesticular, lung, cervical, bladder, head and neck, and ovarian cancersNephrotoxicity, myelosuppression
IfosfamideGerm cell tumoursUrothelial toxicity, myelosuppression
LomustineHodgkin's, malignant melanoma, glioblastoma multiforme and neuroendocrine tumoursMyelosuppression
TemozolomideGlioblastoma multiforme and malignant gliomaHepatotoxicity, myelodysplastic syndromes, secondary malignancy, myelosuppression
Antimetabolites5-Fluorouracil, capecitabineGastrointestinal and breast cancersPatients with DPD deficiency are at increased risk of severe and fatal toxicity, cardiotoxicity, myelosuppression
GemcitabineNon-small cell lung cancer, pancreatic, bladder, ovarian and breast cancersMyelosuppression
PemetrexedMesothelioma and non-small cell lung cancerMyelosuppression
RaltitrexedColorectal cancerMyelosuppression
Antitumor antibioticDoxorubicinOvarian and breast cancersCardiotoxicity, myelosuppression
EpirubicinBreast, gastric, small cell lung, ovarian and colorectal cancersChemical cystitis, myelosuppression
BleomycinGerm cell tumoursPulmonary toxicity, myelosuppression
Topoisomerase inhibitorsIrinotecanColorectal cancerThromboembolism, interstitial lung disease, myelosuppression
EtoposideSmall cell lung cancer and germ cell tumoursMyelosuppression
Mitotic inhibitorsDocetaxelBreast, non-small cell lung cancer, gastric, head and neck, and prostate cancersMyelosuppression, hepatotoxicity
EribulinBreastMyelosuppression
PaclitaxelBreast, ovarian, non-small cell lung cancer and pancreatic cancersCardiotoxicity, interstitial lung disease, myelosuppression
Vincristine, vinorelbineBreast and lung cancersMyelosuppression, peripheral neuropathy
GlucocorticoidsPrednisolone, dexamethasoneMultiple tumour typesAdrenal insufficiency, weight gain, hyperglycaemia
  • DPD = dihydropyrimidine dehydrogenase.